Executive Profiles

An increasing number of small biotech companies are being hatched to focus on a single disease or condition. PharmExec talks to the CEO of one such company, Eugene Williams of Dart Therapeutics.

Shire's new CEO has a simple strategy for success: Set the pace on specialty medicines, spread the positive buzz and momentum of a growth stock, and seize the opportunity to innovate.

This year's HBA Woman of the Year is Merck's Bridgette Heller of Merck Consumer Care.

In 2012, Merck's diabetes franchise became the highest-selling product family in its 122-year history.

Big Pharma takes a fresh licking in our latest audit of US press coverage of business and policy issues.

Are there parallels between milk and medicine? To David Ford, a native New Zealander who now runs Sanofi's North America human resources operations, the answer is a qualified yes.

Pharma's Baby Boomer era is over - now it's the Generation X-ers' turn, says Georg Toufar, Chief Marketing Officer and Board Director of Mundipharma International Limited.

Eric Dube, one of this years Pharm Exec Emerging Pharma Leaders, is not yet 40 and is now GSK's senior VP of strategy after already holding seven "very different" roles at the company.

It's good to look to other industries such as FMCG - and to products such as Pepsi and Horlicks - for lessons in emerging market success, writes Nick Stephens.

Eli Lilly CEO John Lechleiter on his agenda as incoming chairman of PhRMA, US healthcare reform, the euro crisis, and the small problem, of innovation.

Broaden your industry exposure. Think beyond yourself... Timely advice from this year's HBA Woman of the Year, Carolyn Buck Luce.

Throughout her life, HBA Woman of the Year Carolyn Buck-Luce has made progress by recognizing that when one door closes, another one opens.

India's most prominent scientist, Dr R.A. Mashelkar, President of the Global Research Alliance, on delivering medicines profitably but cheaply to low income countries.

Pharm Exec speaks to Bausch + Lomb CEO Brent Saunders about how he turned around "a very troubled company".

Mason Tenaglia offers empirical defense of coupons and copay offset programs.

It's a neck and neck race toward safer, faster, and medically superior treatments. Which organizations have what it takes to jockey their products into the winner's circle?

Pharm Exec sits down with CEO Atsushi Nagahisa to explore how culture can maximize the value of an inherited portfolio

Keeping skittish patients on their medicines ought to be a strategic priority for Big Pharma - but is it? Pharm Exec convenes an expert round table to examine how best to make progress and agree on some practical steps for incorporation in the campaign agenda.

Fred Frank, Vice Chairman, P.J. Solomon Co.

Pharm Exec sits down with Steve Collis, CEO of AmerisourceBergen to discuss his agenda for retooling the drug distribution giant.

Josef von Rickenbach, President & CEO, Parexel

Can cooperative ties between Big Pharma, NGOs, government, and international organizations pay the freight in making the fight against neglected diseases a permanent fix in global health?

A Q&A with Kristin Peck, the drugmaker's Executive Vice President, Worldwide Business Development and Innovation.

A Q&A with Andrew Webber, President and CEO of the National Business Coalition on Health

Taking Onyx Pharmaceuticals to new heights – CEO Tony Coles talks to PharmExec about the midsize company's transition from adolescence to adulthood.